<DOC>
	<DOCNO>NCT02569853</DOCNO>
	<brief_summary>Safety Efficacy DFN-11 patient episodic migraine without aura .</brief_summary>
	<brief_title>DFN-11 Injection Episodic Migraine With Without Aura</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<criteria>1 . If female , subject must negative serum pregnancy test screening , plan become pregnant study , lactate 2 . If female , subject also must negative urine pregnancy test subsequent study visit Screening Visit , agree practice reliable form contraception abstinence study . Acceptable form contraception include implant , injectables , combine oral contraceptive , intrauterine device , vasectomized partner , exclusively female partner , doublebarrier method . 3 . If male ( female partner ) , subject must agree practice reliable form contraception abstinence study . 4 . A history episodic migraine experience 2 6 migraine attack month least past 12 month 14 migraine headache day per month , 48 hour headache free time migraine headache 5 . Have migraine without aura ; aura , aura last longer 60 minute 1 . Minors , even specify study age range 2 . Medication overuse headache define ICHD II : Opioids ≥ 10 day month 90 day prior screen Combination medication ( e.g. , Fiorinal® ) ≥ 10 day month 90 day prior screen Nonsteroidal antiinflammatory drug ( NSAIDs ) simple medication &gt; 14 day month 90 day prior screen Triptans ergots ≥ 10 day month 90 day prior screen 3 . Subjects treat onabotulinumtoxin A ( Botox® ) botulinum toxin treatment ; history receive treatment 180 day prior screen 4 . On unstable dosage migraine prophylactic medication 30 day prior screen 5 . Taking miniprophylaxis menstrual migraine 6 . Subjects hemiplegic basilar migraine form neurologically complicate migraine 7 . Subjects prolong aura ( i.e. , 1 hour ) 8 . Cerebrovascular disease include limited history stroke transient ischemic attack ( TIA ) 9 . A history migralepsy ( seizure follow migraine ) concurrent diagnosis seizure disorder 10 . Subjects differentiate migraine headache tensiontype cluster headache type headache 11 . Subjects history occasional ( base Investigator 's judgment ) tensiontype headache ( distinct migraine headache day count ) . 12 . Subjects history cluster headaches 13 . Subjects diagnosis `` probable migraine '' ( ICHD II ) 14 . Ischemic coronary artery disease ( CAD ) : include limited angina pectoris , history myocardial infarction document silent ischemia coronary artery vasospasm , include Prinzmetal 's angina 15 . Subjects WolffParkinsonWhite syndrome arrhythmia associate cardiac accessory conduction pathway disorder 16 . Subjects history congenital heart disease 17 . A history uncontrolled hypertension screen systolic/diastolic &gt; 140/90 mmHg 18 . Have peripheral vascular disease include limited ischemic bowel disease ( IBD ) Raynaud 's disease . 19 . Any abnormal physiology and/or pathology , opinion Investigator Sponsor , would contraindicate study participation would allow objective study meet 20 . Subjects show clinical laboratory electrocardiogram ( ECG ) abnormality opinion Investigator would endanger subject interfere study conduct . If result clinical laboratory ECG outside normal reference range subject may still enrol finding determine clinically significant Investigator . This determination must record subject 's source document prior enrolment . 21 . Fridericia 's correct QT ( QTcF ) interval great 450 msec 22 . Severe renal impairment ( creatinine &gt; 2 mg/dl ) 23 . Serum total bilirubin &gt; 2.0 mg/dL 24 . Serum aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , alkaline phosphatase &gt; 2.5 time upper limit normal 25 . Subjects uncontrolled diabetes mellitus , glycosylated hemoglobin ( HbA1c ) &gt; 7.0 % , diabetes mellitus require insulin 26 . A history alcohol substance use disorder accord Diagnostic Statistical Manual Mental Disorders , Edition V ( DSMV ) ( include marijuana ) within 1 year prior screen 27 . Current treatment antipsychotic use antipsychotic within 30 day screen 28 . A history current neurological psychiatric impairment , include limited psychosis , current major depression , bipolar disorder cognitive dysfunction , opinion Investigator , would compromise data collection 29 . Subjects receive treatment investigational drug device within 30 day screen visit participate central nervous system clinical trial 3 month prior screen 30 . Subjects medical condition , judgment Investigator and/or Medical Monitor , would confound objective study ( e.g. , positive screen test human immunodeficiency virus [ HIV ] , hepatitis B surface antigen positive hepatitis C positive , known history systemic lupus erythematosis ) 31 . Subjects plan donate blood , sperm , oocytes study 30 day last dose study medication 32 . Subjects employee immediate relative employee Sponsor , affiliate partner , study center</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>